vs
Fortress Biotech, Inc.（FBIO）与ROCKWELL MEDICAL, INC.（RMTI）财务数据对比。点击上方公司名可切换其他公司
ROCKWELL MEDICAL, INC.的季度营收约是Fortress Biotech, Inc.的1.1倍（$17.3M vs $16.1M），ROCKWELL MEDICAL, INC.净利率更高（-9.2% vs -24.5%，领先15.3%），Fortress Biotech, Inc.同比增速更快（6.3% vs -8.5%），过去两年Fortress Biotech, Inc.的营收复合增速更高（11.0% vs -18.2%）
堡垒生物科技（Fortress Biotech）是一家生物制药企业，核心业务为收购、开发并商业化创新医药与生物技术产品。公司由医学博士林赛·A·罗森瓦尔德担任首席执行官，包括绝大多数子公司在内，公司总部均设于佛罗里达州贝港群岛。
罗克韦尔医疗成立于1996年，总部位于美国密歇根州威克瑟姆，是一家上市制药企业，核心业务聚焦于终末期肾病与慢性肾病相关治疗方案的研发与商业化推广。
FBIO vs RMTI — 直观对比
营收规模更大
RMTI
是对方的1.1倍
$16.1M
营收增速更快
FBIO
高出14.7%
-8.5%
净利率更高
RMTI
高出15.3%
-24.5%
两年增速更快
FBIO
近两年复合增速
-18.2%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $16.1M | $17.3M |
| 净利润 | $-3.9M | $-1.6M |
| 毛利率 | 66.1% | 16.8% |
| 营业利润率 | -28.8% | — |
| 净利率 | -24.5% | -9.2% |
| 营收同比 | 6.3% | -8.5% |
| 净利润同比 | 41.8% | — |
| 每股收益（稀释后） | $-0.15 | $-0.04 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FBIORMTI
| Q1 26 | — | $17.3M | ||
| Q4 25 | $16.1M | $18.3M | ||
| Q3 25 | $17.6M | $15.9M | ||
| Q2 25 | $16.4M | $16.1M | ||
| Q1 25 | $13.1M | $18.9M | ||
| Q4 24 | $15.1M | $24.7M | ||
| Q3 24 | $14.6M | $28.3M | ||
| Q2 24 | $14.9M | $25.8M |
净利润FBIORMTI
| Q1 26 | — | $-1.6M | ||
| Q4 25 | $-3.9M | $-554.0K | ||
| Q3 25 | $5.8M | $-1.8M | ||
| Q2 25 | $15.5M | $-1.5M | ||
| Q1 25 | $-10.6M | $-1.5M | ||
| Q4 24 | $-6.8M | $-756.0K | ||
| Q3 24 | $-12.9M | $1.7M | ||
| Q2 24 | $-10.9M | $343.0K |
毛利率FBIORMTI
| Q1 26 | — | 16.8% | ||
| Q4 25 | 66.1% | 21.1% | ||
| Q3 25 | 67.4% | 14.3% | ||
| Q2 25 | 69.9% | 15.6% | ||
| Q1 25 | 63.5% | 16.1% | ||
| Q4 24 | 69.1% | 14.7% | ||
| Q3 24 | 69.4% | 22.0% | ||
| Q2 24 | 61.6% | 17.6% |
营业利润率FBIORMTI
| Q1 26 | — | — | ||
| Q4 25 | -28.8% | -2.2% | ||
| Q3 25 | -38.6% | -9.9% | ||
| Q2 25 | -222.2% | -8.4% | ||
| Q1 25 | -169.9% | -7.2% | ||
| Q4 24 | -158.3% | -2.1% | ||
| Q3 24 | -151.0% | 6.8% | ||
| Q2 24 | -186.5% | 2.0% |
净利率FBIORMTI
| Q1 26 | — | -9.2% | ||
| Q4 25 | -24.5% | -3.0% | ||
| Q3 25 | 33.2% | -11.0% | ||
| Q2 25 | 94.4% | -9.3% | ||
| Q1 25 | -80.6% | -8.0% | ||
| Q4 24 | -44.7% | -3.1% | ||
| Q3 24 | -88.0% | 5.9% | ||
| Q2 24 | -73.5% | 1.3% |
每股收益（稀释后）FBIORMTI
| Q1 26 | — | $-0.04 | ||
| Q4 25 | $-0.15 | $-0.01 | ||
| Q3 25 | $0.11 | $-0.05 | ||
| Q2 25 | $0.45 | $-0.05 | ||
| Q1 25 | $-0.48 | $-0.04 | ||
| Q4 24 | $-0.16 | $-0.02 | ||
| Q3 24 | $-0.76 | $0.04 | ||
| Q2 24 | $-0.73 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $79.4M | — |
| 总债务越低越好 | $52.4M | — |
| 股东权益账面价值 | $49.9M | $35.9M |
| 总资产 | $185.5M | $57.4M |
| 负债/权益比越低杠杆越低 | 1.05× | — |
8季度趋势，按日历期对齐
现金及短期投资FBIORMTI
| Q1 26 | — | — | ||
| Q4 25 | $79.4M | $10.7M | ||
| Q3 25 | $86.2M | $13.6M | ||
| Q2 25 | $74.4M | $12.5M | ||
| Q1 25 | $91.3M | $11.4M | ||
| Q4 24 | $57.3M | $15.7M | ||
| Q3 24 | $58.9M | $12.3M | ||
| Q2 24 | $76.2M | $11.9M |
总债务FBIORMTI
| Q1 26 | — | — | ||
| Q4 25 | $52.4M | — | ||
| Q3 25 | $47.8M | — | ||
| Q2 25 | $50.0M | — | ||
| Q1 25 | $56.4M | — | ||
| Q4 24 | $58.0M | — | ||
| Q3 24 | $52.5M | — | ||
| Q2 24 | $67.0M | — |
股东权益FBIORMTI
| Q1 26 | — | $35.9M | ||
| Q4 25 | $49.9M | $37.0M | ||
| Q3 25 | $55.9M | $37.0M | ||
| Q2 25 | $43.9M | $30.4M | ||
| Q1 25 | $22.3M | $31.5M | ||
| Q4 24 | $22.7M | $32.6M | ||
| Q3 24 | $21.2M | $29.1M | ||
| Q2 24 | $17.9M | $23.5M |
总资产FBIORMTI
| Q1 26 | — | $57.4M | ||
| Q4 25 | $185.5M | $57.1M | ||
| Q3 25 | $181.4M | $57.5M | ||
| Q2 25 | $159.9M | $52.6M | ||
| Q1 25 | $178.1M | $54.0M | ||
| Q4 24 | $144.2M | $59.2M | ||
| Q3 24 | $127.1M | $57.1M | ||
| Q2 24 | $145.7M | $53.0M |
负债/权益比FBIORMTI
| Q1 26 | — | — | ||
| Q4 25 | 1.05× | — | ||
| Q3 25 | 0.86× | — | ||
| Q2 25 | 1.14× | — | ||
| Q1 25 | 2.53× | — | ||
| Q4 24 | 2.55× | — | ||
| Q3 24 | 2.48× | — | ||
| Q2 24 | 3.75× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-12.5M | — |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流FBIORMTI
| Q1 26 | — | — | ||
| Q4 25 | $-12.5M | $2.3M | ||
| Q3 25 | $-6.1M | $-1.3M | ||
| Q2 25 | $-27.6M | $1.8M | ||
| Q1 25 | $-19.6M | $-3.5M | ||
| Q4 24 | $-12.9M | $865.0K | ||
| Q3 24 | $-20.1M | $4.3M | ||
| Q2 24 | $-21.8M | $1.4M |
自由现金流FBIORMTI
| Q1 26 | — | — | ||
| Q4 25 | — | $2.2M | ||
| Q3 25 | — | $-1.5M | ||
| Q2 25 | — | $1.7M | ||
| Q1 25 | — | $-3.5M | ||
| Q4 24 | — | $470.0K | ||
| Q3 24 | — | $4.1M | ||
| Q2 24 | — | $1.2M |
自由现金流率FBIORMTI
| Q1 26 | — | — | ||
| Q4 25 | — | 12.0% | ||
| Q3 25 | — | -9.6% | ||
| Q2 25 | — | 10.5% | ||
| Q1 25 | — | -18.8% | ||
| Q4 24 | — | 1.9% | ||
| Q3 24 | — | 14.4% | ||
| Q2 24 | — | 4.5% |
资本支出强度FBIORMTI
| Q1 26 | — | — | ||
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 1.4% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | 1.6% | ||
| Q3 24 | 0.0% | 0.7% | ||
| Q2 24 | — | 1.1% |
现金转化率FBIORMTI
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | -1.04× | — | ||
| Q2 25 | -1.78× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.57× | ||
| Q2 24 | — | 4.20× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
